DGAP-News: Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead
(firmenpresse) - Genmab A/S
17.06.2013 07:31
---------------------------------------------------------------------------
Media Release
-- Antibody-drug conjugate (ADC) to be developed for cancer
-- Combines strength of HuMax(r)-TAC with next generation PBD-based warhead
technology
-- 50:50 partnership
Copenhagen, Denmark and Lausanne, Switzerland; June 17, 2013 - Genmab A/S (OMX:
GEN) and ADC Therapeutics Sarl announced today an agreement to develop a new
antibody-drug conjugate (ADC) product combining Genmab's HuMax-TAC antibody and
ADC Therapeutics' PBD-based warhead and linker technology. The Companies have
been conducting in vitro and in vivo studies since 2012 to investigate
different warhead and linker combinations with HuMax-TAC, and now have the
product ready for pre-IND preclinical development. The product will be
developed for multiple cancer indications.
Genmab and ADC Therapeutics will each initially have an equal share in the
product. In the first instance, ADC Therapeutics will lead and fund preclinical
development. Prior to the submission of an application to conduct clinical
studies in patients (IND filing), Genmab may elect to retain equal ownership of
the product. Genmab will not incur any development costs prior to the IND
filing decision and Genmab will maintain a minimum 25% ownership stake in the
product as it moves into clinical development. No other financial terms were
disclosed.
'We believe our unique HuMax-TAC antibody has optimal characteristics for
creation of an ultra-potent antibody-drug conjugate when used in combination
with ADC Therapeutics' novel PBD-based warhead and linker technology, which
employs an emerging class of highly potent anticancer agents. This agreement
is another example of a win-win partnership combining Genmab's state-of-the-art
antibody development expertise with the latest advance in antibody-payload
technology,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Dr. Peter B. Corr, Chairman of ADC Therapeutics said: 'We are very excited to
be developing an ADC with our new partner Genmab and incorporating our next
generation PBD-based toxins into this product. Our warhead payload technology
enjoys exquisite potency, optimised conjugation and pharmaceutical properties
that maintain activity in highly resistant cancers. Our pre-clinical data for
this product indicate the potential for curative efficacy in highly resistant
populations at low ADC doses of this product in several oncology indications,
an area with critical unmet needs'.
This agreement does not affect Genmab's 2013 financial guidance.
About HuMax-TAC
HuMax-TAC is a high-affinity fully human antibody targeting CD25, a therapeutic
target with strong clinical validation. CD25 is expressed on a variety of
hematological tumors and shows limited expression on normal tissues, which
makes it a very attractive target for antibody-payload approaches. With
HuMax-TAC-ADC, we aim to develop a first-in-class antibody-drug conjugate for
the potential treatment of CD25-expressing lymphomas and leukemias.
About PBD Warheads&Linkers
ADCs developed using ADC Therapeutics' technology combine monoclonal antibodies
specific to particular tumor targets with highly potent pyrrolobenzodiazepine
(PBD) based warheads developed by ADC Therapeutic's partner Spirogen Limited.
These PBD warheads are joined to antibodies by linkers that release the PBD
warhead in the targeted cancer cells. This technology has attracted the
attention of other biotechnology companies such as Genentech and Seattle
Genetics.
About ADC Therapeutics
ADC Therapeutics Sarl (ADCT) is a Swiss-based oncology drug development company
that specializes in the development of proprietary Antibody Drug Conjugates
(ADCs) targeting major cancers such as breast, lung, prostate, renal and blood.
The Company's ADCs are highly targeted drug constructs which combine monoclonal
antibodies specific to particular types of tumor cells with a novel class of
highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based
chemistries do not distort the structure of the DNA it gives the prospect of
highly potent, target-selective cancer therapies with fewer side effects and
the potential to pre-empt resistance issues faced by other anti-cancer products
on the market. The company was formed in 2012 with a $50m commitment from
private equity firm Auven Therapeutics (previously known as Celtic
Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an
Auven Therapeutics' portfolio company, for the supply of warhead chemistries
and R&D services. It operates a virtual business model based in Lausanne,
Switzerland.
For further information please see:www.adctherapeutics.com.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact Genmab:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations&Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen(at)genmab.com
Contact ADC Therapeutics:
Sue Charles/Stefanie Bacher/Gemma Howe, College Hill Life Sciences (PR Agency
for ADC Therapeutics)
T: +44 (0) 20 7457 202; E: adct(at)collegehill.com
This Media Release contains forward looking statements. The words 'believe',
'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Media Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); DuoBody(r), HexaBody(TM) and
UniBody(r). Arzerra(r) is a trademark of GlaxoSmithKline.
Media Release no. 04
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=436098
News Source: NASDAQ OMX
17.06.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
genmab-and-adc-therapeutics-enter-co
development-collaboration-for-an-antibody
drug-conjugate-combining-humax
tac-and-pbd-warhead
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 270062
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 435 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead"
steht unter der journalistisch-redaktionellen Verantwortung von
Genmab A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
